Cargando…

Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells

PURPOSE: T-DM1 is an antibody–drug conjugate (ADC) consisting of trastuzumab and DM1 linked together. T-DM1 binds to human epidermal growth factor receptor-2 (HER2) in tumors and then triggers the endocytosis of T-DM1 and release of payload. Therefore, endocytosis efficacy is considered as a critica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Keying, Mei, Shengsheng, Gao, Xiangzheng, Peng, Shanshan, Zhan, Jinbiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713712/ https://www.ncbi.nlm.nih.gov/pubmed/34992350 http://dx.doi.org/10.2147/DDDT.S344052

Ejemplares similares

An efficient system to generate truncated human angiotensin converting enzyme 2 (hACE2) capable of binding RBD and spike protein of SARS-CoV2
por: Gao, Xiangzheng, et al.
Publicado: (2021)

Virulent Drexlervirial Bacteriophage MSK, Morphological and Genome Resemblance With Rtp Bacteriophage Inhibits the Multidrug-Resistant Bacteria
por: Khan, Muhammad Saleem Iqbal, et al.
Publicado: (2021)

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017)

Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy
por: Kalim, Muhammad, et al.
Publicado: (2020)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
por: Girish, Sandhya, et al.
Publicado: (2012)

Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
por: Kalim, Muhammad, et al.
Publicado: (2017)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Rapid Evaluation of Antibody Fragment Endocytosis for Antibody Fragment–Drug Conjugates
por: Kim, Eunhee G., et al.
Publicado: (2020)

Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
por: Ritchie, Michael, et al.
Publicado: (2013)

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
por: Najjar, Mariana K., et al.
Publicado: (2022)

Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)
por: Chung, Yuan-Chiang, et al.
Publicado: (2015)

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
por: Lu, Dan, et al.
Publicado: (2014)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells
por: Chiang, Zu-Chian, et al.
Publicado: (2020)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
por: English, Diana P, et al.
Publicado: (2014)

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
por: Nadal-Serrano, Mercedes, et al.
Publicado: (2020)

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates
por: Ding, Haozhong, et al.
Publicado: (2019)

Strategic Trastuzumab Mediated Crosslinking Driving Concomitant HER2 and HER3 Endocytosis and Degradation in Breast Cancer
por: Wymant, Jennifer Mary, et al.
Publicado: (2020)

Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment–Drug Conjugates Carrying Maytansinoids DM1 and DM4
por: Kalinovsky, Daniel V., et al.
Publicado: (2023)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS
por: van den Berg, Eline B. A., et al.
Publicado: (2022)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1
por: Islam, Syed S., et al.
Publicado: (2019)

An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
por: Shin, Seol Hwa, et al.
Publicado: (2021)

Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
por: Maneiro, María, et al.
Publicado: (2020)

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
por: Ferraro, Emanuela, et al.
Publicado: (2021)

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
por: Escrivá-de-Romaní, Santiago, et al.
Publicado: (2023)

Melatonin potentiates the cytotoxic effect of Neratinib in HER2(+) breast cancer through promoting endocytosis and lysosomal degradation of HER2
por: Liu, Zundong, et al.
Publicado: (2021)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

HER2 expression and efficacy of T-DM1
por: Montemurro, Filippo
Publicado: (2014)

Development and Characterization of a Novel Peptide—Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors
por: Wang, Yayu, et al.
Publicado: (2021)

Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
por: Ma, Bo, et al.
Publicado: (2016)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis
por: Takahashi, Jun-ichiro, et al.
Publicado: (2022)

Delivery of Drugs into Cancer Cells Using Antibody–Drug Conjugates Based on Receptor-Mediated Endocytosis and the Enhanced Permeability and Retention Effect
por: Tashima, Toshihiko
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cki56bfk5fsr8ssil7r074ebe6